Citigroup’s Legend Biotech LEGN Stock Holding History

Citigroup’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.08M	Buy	72,000 +42,000	+140%	+$1.13M	﹤0.01%	2900
2026 Q1	$543K	Hold	30,000	–	–	﹤0.01%	3503
2025 Q4	$652K	Buy	30,000 +15,000	+100%	+$430K	﹤0.01%	3420
2025 Q3	$489K	Sell	15,000 -15,000	-50%	-$554K	﹤0.01%	3591
2025 Q2	$1.06M	Sell	30,000 -56,400	-65%	-$1.83M	﹤0.01%	3155
2025 Q1	$2.93M	Buy	86,400 +56,400	+188%	+$2.02M	﹤0.01%	2370
2024 Q4	$976K	Buy	+30,000	New	+$1.24M	﹤0.01%	3389
2023 Q4	–	Sell	-24,900	Closed	-$1.67M	–	5793
2023 Q3	$1.67M	Buy	+24,900	New	+$1.73M	﹤0.01%	2113
2023 Q2	–	Sell	-29,800	Closed	-$1.44M	–	5658
2023 Q1	$1.44M	Buy	+29,800	New	+$1.46M	﹤0.01%	2257
2022 Q4	–	Sell	-29,800	Closed	-$1.22M	–	5864
2022 Q3	$1.22M	Buy	29,800 +14,000	+89%	+$657K	﹤0.01%	2562
2022 Q2	$869K	Sell	15,800 -4,200	-21%	-$177K	﹤0.01%	2778
2022 Q1	$727K	Buy	+20,000	New	+$790K	﹤0.01%	3228

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Citigroup's LEGN Position: Q2 2026 in Review

Citigroup reduced its Legend Biotech (LEGN) stake by 30% in Q2 2026, selling an estimated $639K and leaving 56,247 shares worth $1.62M. The position accounts for ﹤0.01% of the portfolio, ranked #3087.

Citigroup first reported a position in LEGN in Q4 2020 and has held it in 23 quarters since. The position peaked at $6.29M in Q2 2022. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

Citigroup held 56,247 shares of Legend Biotech worth $1.62M as of Q2 2026.
Citigroup sold 23,702 Legend Biotech shares in Q2 2026, an estimated $639K.
Legend Biotech made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3087 holding.
Citigroup first reported a position in Legend Biotech in Q4 2020 and has held it in 23 quarters since.
Citigroup's Legend Biotech position peaked at $6.29M in Q2 2022.
219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.